Select a Region North America

Expertise

Chris Cameron headshot

Chris Cameron, PhD

Chief Scientific Officer

Expertise:

Clinical Trials, Data and Software, HEOR, Pricing, Reimbursement & Market Access, Regulatory, RWE

Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and lead of Health Economics at CADTH. He has also been a consultant decision scientist for ICER, a member of the Economic Guidance Panel at pCODR, and served on PMPRB Technical Panel on drug pricing guidelines in Canada. Chris is an adjunct (scholar) professor at Dalhousie University, and has authored over 100 peer-reviewed publications in many of the world’s top journals, including JAMA, Lancet, and BMJ. His research has been featured in the Globe and Mail and New York Times. He was recently named one of the most prolific authors in the world on indirect treatment comparisons, and was a co-author on the PRISMA NMA reporting guidelines.

Chris holds a bachelor’s degree in Mathematics and an MSc and PhD in Epidemiology where he was a Vanier Canada Graduate Scholar. He also completed a fellowship on real-world data analytics at Harvard University and FDA’s Sentinel Initiative, and the Oxford Artificial Intelligence Programme.

Articles by Chris Cameron, PhD

The AI Revolution in HEOR: How ChatGPT-4o and Multi-AI Agents Are Shaping

Discover the future of Health Economics and Outcomes Research (HEOR) in our article, ‘The AI Revolution in HEOR’. Learn how AI, particularly ChatGPT-4o, is transforming the field with its enhanced speed and capabilities. Explore the potential of multi-AI agents in augmenting HEOR workflows and the emerging role of AI in supporting core HEOR services. This […]

A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices

Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national […]

Decoding EMA’s Blueprint on Real-World Evidence

The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from RWD analysis, within the scope of regulatory decision-making. It details the types of studies that can be conducted, how […]

Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs

Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs The Institute for Clinical and Economic Review (ICER) has recently updated its protocol for assessing unsupported price increases of prescription drugs. This initiative provides a transparent and systematic approach to evaluate whether substantial price hikes in medications in the United States are justified […]

Empowering Success: EVERSANA’s Value & Evidence Team Guides Clients Through CMS Drug Negotiations Under the Inflation Reduction Act

Authors: Chris Cameron, Kerise Clarke, Barkha Patel, Amanda Griffin In anticipation of CMS’s announcement of the first 10 drugs to be selected for negotiations through the Inflation Reduction Act on September 1, 2023, we partnered to support our clients as they faced the prospect of selection. Our engagement began well before the announcement date to […]

What EVERSANA’s Growing Abstract Count at ISPOR U.S. Means to the HEOR Industry

EVERSANA’s Value & Evidence (V&E) and Data & Analytics (D&A) team collectively had an impressive 27 abstracts accepted to ISPOR U.S. 2023, showcasing EVERSANA’s ability to cross-solve for clients’ HEOR needs.   EVERSANA’s Value & Evidence and Data & Analytics teams have had 27 abstracts accepted to ISPOR U.S. 2023, the leading global conference for health […]

ISPOR 2020 WORKSHOP: Developing Global Indirect Treatment Comparison Programs for Market Access

DEVELOPING AND IMPLEMENTING AN INDIRECT TREATMENT COMPARISON (ITC) PROGRAM TO SUPPORT GLOBAL HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT SUBMISSIONS Virtual ISPOR 2020 | WEDNESDAY, May 20th, 2020 | 10:00 AM ET PURPOSE: This interactive workshop will examine the various indirect comparison methodologies that are available. Commonly used ITC methods such as network meta-analysis (NMA) and matching-adjusted […]

ISPOR 2020 PODIUM: PSM and Bayesian Hierarchical Design Methods to Integrate Single-Arm Studies into NMAs in Lung Cancer

APPLICATION OF PROPENSITY SCORE MATCHING AND BAYESIAN HIERARCHICAL DESIGN METHODS TO INTEGRATE SINGLE-ARM STUDIES INTO NETWORK META-ANALYSES (NMAS): Opportunities and Pitfalls Illustrated in a Case Study Assessing Ablation/Radiation Therapies in Lung Cancer Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:45-6:00 PM ET OBJECTIVES: Network meta-analyses (NMAs) generally include direct comparative evidence from randomized […]

ISPOR 2020 PODIUM: Methodological Challenges with NMAs Assessing Long-term Efficacy in Psoriasis

METHODOLOGICAL CHALLENGES WITH CONDUCTING NETWORK META-ANALYSES ASSESSING LONG-TERM COMPARATIVE EFFICACY IN PSORIASIS- A CRITIQUE OF ASSUMPTIONS UNDERPINNING RECENT INDIRECT TREATMENT COMPARISONS Virtual ISPOR 2020 | TUESDAY, May 19th, 2020 | 5:30-5:45 PM ET OBJECTIVES: In network meta-analysis (NMA) of psoriasis trials, cross-over after an initial placebo-controlled period limits the connectivity of long-term evidence networks. We illustrate […]

Interested in scheduling a meeting or speaking event?

Contact Us